Vietnam reports 5,637new COVID-19 cases, 70 more deaths on Tuesday
03/11/21 13:55
HANOI, Oct 30 (VNS) - Viet Nam reports 5,637 cases of COVID-19 on Tuesday, bringing total cases to 932,357.

Twenty-four imported and 5,613 domestic infections were confirmed on Tuesday.

An additional 70 COVID-related deaths were also announced, bringing the total death toll to 22,205.
- FRESH NEWS

'Grave concern' over Covid in Europe as German cases soar
published : 4 Nov 2021 at 19:45
writer: AFP
Relaxed protective measures like mask-wearing may have contributed to soaring cases in countries like Germany.

FRANKFURT: The World Health Organization expressed "grave concern" Thursday over the rising pace of coronavirus infections in Europe, as Germany registered its biggest daily increase since the start of the pandemic.

"We are, once again, at the epicentre," WHO Europe director Hans Kluge told a press conference.

He warned that according to "one reliable projection" the current trajectory would mean "another half a million Covid-19 deaths" by February.

Alarm bells were ringing especially in Germany, the European Union's most populous country, where the number of new cases over the past 24 hours soared to almost 34,000 on Thursday -- an all-time high, according to the Robert Koch Institute health agency.

Meanwhile Britain on Thursday became the first country in the world to approve the use of Merck's anti-Covid pill to treat patients suffering from mild to moderate coronavirus infections.

Health minister Sajid Javid called the molnupiravir antiviral "a game-changer for the most vulnerable and the immunosuppressed".

German Health Minister Jens Spahn said on Wednesday that the country of 83 million people was facing a "massive" pandemic among the unvaccinated and that intensive care beds were starting to run out in some regions.

"Corona is once again raging with full force, the fourth wave is hitting us hard," the top-selling Bild daily wrote.

The WHO's Europe region -- which spans 53 countries and territories and includes several nations in Central Asia -- has now recorded 78 million cases since Covid-19 first emerged in China in late 2019.

The cumulative figure exceeds that of South East Asia, the Eastern Mediterranean region, the Western Pacific, and Africa combined, the organisation said.

The "current pace of transmission" across the European region "is of grave concern", Kluge said.

The WHO blamed a combination of insufficient vaccination rates and a relaxation of preventative measures like mask-wearing and social distancing.

Hospital admission rates were higher in countries where fewer people are vaccinated, Kluge added.

The number of new daily cases has been rising for nearly six consecutive weeks in Europe and the number of new deaths per day has been rising for just over seven consecutive weeks, with about 250,000 cases and 3,600 deaths per day, according to official national data compiled by AFP.
https://www.bangkokpost.com/world/22097 ... cases-soar

More on the current European Covid-19 surge, 4 November 2021.

Cambodia News: The latest figures from Santé publique France have announced 9502 new cases of Covid-19 in France, over 24 hours on Thursday, 4 November, which is an increase of 47% compared to the figures last Thursday.*
https://www.lci.fr/sante/en-direct-covi ... 96156.html
* Rough translation from French.

Pfizer says COVID-19 pill cut hospital, death risk by 90%

WASHINGTON (AP) — Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market.

Currently all COVID-19 treatments used in the U.S. require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.

Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months. If authorized the company would sell the drug under the brand name Paxlovid.

Researchers worldwide have been racing to find a pill against COVID-19 that can be taken at home to ease symptoms, speed recovery and reduce the crushing burden on hospitals and doctors.
Pfizer released preliminary results Friday of its study of 775 adults. Patients who received the company's drug along with another antiviral shortly after showing COVID-19 symptoms had an 89% reduction in their combined rate of hospitalization or death after a month, compared to patients taking a dummy pill. Fewer than 1% of patients taking the drug needed to be hospitalized and no one died. In the comparison group, 7% were hospitalized and there were seven deaths.

"We were hoping that we had something extraordinary, but it’s rare that you see great drugs come through with almost 90% efficacy and 100% protection for death,” said Dr. Mikael Dolsten, Pfizer’s chief scientific officer, in an interview.

Study participants were unvaccinated, with mild-to-moderate COVID-19, and were considered high risk for hospitalization due to health problems like obesity, diabetes or heart disease. Treatment began within three to five days of initial symptoms, and lasted for five days. Patients who received the drug earlier showed slightly better results, underscoring the need for speedy testing and treatment.
Pfizer reported few details on side effects but said rates of problems were similar between the groups at about 20%.

An independent group of medical experts monitoring the trial recommended stopping it early, standard procedure when interim results show such a clear benefit. The data have not yet been published for outside review, the normal process for vetting new medical research.

Top U.S. health officials continue to stress that vaccination will remain the best way to protect against infection. But with tens of millions of adults still unvaccinated — and many more globally — effective, easy-to-use treatments will be critical to curbing future waves of infections.

The FDA has set a public meeting later this month to review Merck’s pill, known as molnupiravir. The company reported in September that its drug cut rates of hospitalization and death by 50%. Experts warn against comparing preliminary results because of differences in studies.

Although Merck's pill is further along in the U.S. regulatory process, Pfizer's drug could benefit from a safety profile that is more familiar to regulators with fewer red flags. While pregnant women were excluded from the Merck trial due to a potential risk of birth defects, Pfizer’s drug did not have any similar restrictions. The Merck drug works by interfering with the coronavirus' genetic code, a novel approach to disrupting the virus.

Pfizer’s drug is part of a decades-old family of antiviral drugs known as protease inhibitors, which revolutionized the treatment of HIV and hepatitis C. The drugs block a key enzyme which viruses need to multiply in the human body.

The drug was first identified during the SARS outbreak originating in Asia during 2003. Last year, company researchers decided to revive the medication and study it for COVID-19, given the similarities between the two coronaviruses.

The U.S. has approved one other antiviral drug for COVID-19, remdesivir, and authorized three antibody therapies that help the immune system fight the virus. But they have to be given by IV or injection at hospitals or clinics, and limited supplies were strained by the last surge of the delta variant.

Shares of Pfizer spiked more than 9% before the opening bell Friday.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

https://www.msn.com/en-xl/news/other/pf ... hp&pc=U531

Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market.

Meanwhile Britain on Thursday became the first country in the world to approve the use of Merck's anti-Covid pill to treat patients suffering from mild to moderate coronavirus infections.

Health minister Sajid Javid called the molnupiravir antiviral "a game-changer for the most vulnerable and the immunosuppressed".

These pills are going to be highly sought after, providing they work as well as the studies suggest.

If you can buy a course of treatment and keep them with you for when travelling or living in countries with crappy healthcare systems, if get infected you can give yourself first rate healthcare from the comfort of you living room.

Sod the Ivermectin, this sounds like what you want to get your hands on and keep in your medicine cabinet. They could sell billions of the things, most of which will go unused.

The counterfeiters of the world must be licking their lips...

Doc67 wrote: ↑Sat Nov 06, 2021 8:03 am

Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market.

Meanwhile Britain on Thursday became the first country in the world to approve the use of Merck's anti-Covid pill to treat patients suffering from mild to moderate coronavirus infections.

Health minister Sajid Javid called the molnupiravir antiviral "a game-changer for the most vulnerable and the immunosuppressed".

These pills are going to be highly sought after, providing they work as well as the studies suggest.

If you can buy a course of treatment and keep them with you for when travelling or living in countries with crappy healthcare systems, if get infected you can give yourself first rate healthcare from the comfort of you living room.

Sod the Ivermectin, this sounds like what you want to get your hands on and keep in your medicine cabinet. They could sell billions of the things, most of which will go unused.

The counterfeiters of the world must be licking their lips...

Up to now you're quote "the counterfeiters of the world must be licking their lips..." the Chinese must be licking their lips, because I think they are the only ones up to now to sell Covid19 vaccines.

https://www.infosecurity-magazine.com/n ... _view=true

Not exactly about the Coronavirus, but it is related. Something that has been a growing issue. I guess when you get a bunch of programmers fired from their jobs for being non-essential they figure out "Creative" ways to make money.

Doc67 wrote: ↑Sat Nov 06, 2021 8:03 am

Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market.

Meanwhile Britain on Thursday became the first country in the world to approve the use of Merck's anti-Covid pill to treat patients suffering from mild to moderate coronavirus infections.

Health minister Sajid Javid called the molnupiravir antiviral "a game-changer for the most vulnerable and the immunosuppressed".

These pills are going to be highly sought after, providing they work as well as the studies suggest.

If you can buy a course of treatment and keep them with you for when travelling or living in countries with crappy healthcare systems, if get infected you can give yourself first rate healthcare from the comfort of you living room.

Sod the Ivermectin, this sounds like what you want to get your hands on and keep in your medicine cabinet. They could sell billions of the things, most of which will go unused.

The counterfeiters of the world must be licking their lips...

John Campbell does a deep dive on the new Pfizer drug, looking at the technical details of how it works, using top notch published articles. It turns out it works very well, but not as well as Ivermectin. Btw, Remdesivir is almost useless.
Remdesivir costs $700 per course of treatment, the new Pfeizer drug will cost something similar. Ivermectin costs 6 cents. And no worries about unknown latent risks from Ivermectin because it has been taken by billions of people as a treatment for scabies and is proven to be one of the safesr drugs ever used.
But, hey the media says let's focus on the new Pfizer wonderdrug and ignore or villify Ivermectin.

For anyone who gets triggered by the word Ivermectin, try this mental exercise. Hold on to two seemingly oppsite thoughts simultaneously - vaccines are good and Ivermectin is good. You can do it if you discard the media brainwashing for an instant.